CA2193681A1 - New oral pharmaceutical formulation containing magnesium salt of omeprazole - Google Patents
New oral pharmaceutical formulation containing magnesium salt of omeprazoleInfo
- Publication number
- CA2193681A1 CA2193681A1 CA002193681A CA2193681A CA2193681A1 CA 2193681 A1 CA2193681 A1 CA 2193681A1 CA 002193681 A CA002193681 A CA 002193681A CA 2193681 A CA2193681 A CA 2193681A CA 2193681 A1 CA2193681 A1 CA 2193681A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation according
- enteric
- formulation
- enteric coating
- omeprazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9400679 | 1994-07-08 | ||
WOPCT/SE94/00679 | 1994-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2193681A1 true CA2193681A1 (en) | 1996-01-25 |
Family
ID=20393105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002193681A Abandoned CA2193681A1 (en) | 1994-07-08 | 1995-07-03 | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0768872A1 (fi) |
KR (1) | KR970704426A (fi) |
BR (1) | BR9508261A (fi) |
CA (1) | CA2193681A1 (fi) |
CZ (1) | CZ379596A3 (fi) |
EE (1) | EE03378B1 (fi) |
FI (1) | FI970058A0 (fi) |
HU (1) | HUT78132A (fi) |
IS (1) | IS4398A (fi) |
MX (1) | MX9700152A (fi) |
NO (1) | NO970036D0 (fi) |
NZ (1) | NZ289958A (fi) |
PL (1) | PL181265B1 (fi) |
SK (1) | SK166096A3 (fi) |
WO (1) | WO1996001622A1 (fi) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US5900258A (en) * | 1996-02-01 | 1999-05-04 | Zeolitics Inc. | Anti-bacterial compositions |
SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
CA2413923A1 (en) * | 2000-03-09 | 2001-09-13 | Andrew Ilchyshyn | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
EP1133987A1 (en) * | 2000-03-09 | 2001-09-19 | Ian Whitcroft | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
EP1552833B1 (en) | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CA2570796A1 (en) * | 2004-06-15 | 2006-01-05 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of benzimidazole compounds |
CN105106168B (zh) * | 2015-08-19 | 2018-03-06 | 德州德药制药有限公司 | 一种埃索美拉唑镁肠胶囊及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
-
1995
- 1995-07-03 MX MX9700152A patent/MX9700152A/es unknown
- 1995-07-03 EE EE9700014A patent/EE03378B1/xx not_active IP Right Cessation
- 1995-07-03 CA CA002193681A patent/CA2193681A1/en not_active Abandoned
- 1995-07-03 HU HU9700039A patent/HUT78132A/hu unknown
- 1995-07-03 WO PCT/SE1995/000816 patent/WO1996001622A1/en not_active Application Discontinuation
- 1995-07-03 BR BR9508261A patent/BR9508261A/pt not_active Application Discontinuation
- 1995-07-05 CZ CZ963795A patent/CZ379596A3/cs unknown
- 1995-07-05 NZ NZ289958A patent/NZ289958A/en unknown
- 1995-07-05 SK SK1660-96A patent/SK166096A3/sk unknown
- 1995-07-05 PL PL95318464A patent/PL181265B1/pl unknown
- 1995-07-05 EP EP95926067A patent/EP0768872A1/en not_active Withdrawn
- 1995-07-05 KR KR1019970700059A patent/KR970704426A/ko not_active Application Discontinuation
-
1996
- 1996-12-17 IS IS4398A patent/IS4398A/is unknown
-
1997
- 1997-01-06 NO NO970036A patent/NO970036D0/no not_active Application Discontinuation
- 1997-01-07 FI FI970058A patent/FI970058A0/fi unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6780435B2 (en) | 1997-11-14 | 2004-08-24 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6855336B2 (en) | 1998-08-28 | 2005-02-15 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
Also Published As
Publication number | Publication date |
---|---|
WO1996001622A1 (en) | 1996-01-25 |
WO1996001622A8 (en) | 1999-12-23 |
KR970704426A (ko) | 1997-09-06 |
PL181265B1 (pl) | 2001-06-29 |
BR9508261A (pt) | 1997-12-23 |
FI970058A (fi) | 1997-01-07 |
HUT78132A (hu) | 2000-06-28 |
AU695723B2 (en) | 1998-08-20 |
PL318464A1 (en) | 1997-06-09 |
SK166096A3 (en) | 1997-09-10 |
NO970036L (no) | 1997-01-06 |
CZ379596A3 (en) | 1997-08-13 |
MX9700152A (es) | 1997-04-30 |
IS4398A (is) | 1996-12-17 |
NO970036D0 (no) | 1997-01-06 |
NZ289958A (en) | 1998-09-24 |
EE9700014A (et) | 1997-06-16 |
HU9700039D0 (en) | 1997-02-28 |
FI970058A0 (fi) | 1997-01-07 |
EP0768872A1 (en) | 1997-04-23 |
EE03378B1 (et) | 2001-04-16 |
AU2994795A (en) | 1996-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2290531C (en) | Pharmaceutical formulation of omeprazole | |
CA2193681A1 (en) | New oral pharmaceutical formulation containing magnesium salt of omeprazole | |
EP0502556B1 (en) | Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds | |
CA2166483C (en) | New pharmaceutical formulation | |
JP4183746B2 (ja) | 酸不安定性ベンズイミダゾールを含有する新規安定型ガレニック製剤、及びその製造方法 | |
EP1746980B1 (en) | Pharmaceutical dosage form comprising pellets as well as its manufacturing process | |
EP0941074B1 (en) | Delayed delivery system for acid-sensitive drugs | |
JPS62258320A (ja) | 内服用新規医薬製剤 | |
KR20010075685A (ko) | 오메프라졸을 포함하는 제약 제형 | |
KR20080070841A (ko) | 아세틸 살리실산과 함께 프로톤 펌프 억제제를 활성성분으로 포함하는 경구용 약제학적 투약형 | |
WO2006085335A2 (en) | Pharmaceutical composition of acid labile substances | |
WO2005034924A1 (en) | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation | |
WO2007054565A2 (en) | New stabilized galenic formulations comprising lansoprazole and their preparation | |
AU695723C (en) | New oral pharmaceutical formulation containing magnesium salt of omeprazole | |
JPH10504288A (ja) | オメプラゾールのマグネシウム塩を含有する新規な経口医薬処方物 | |
MXPA99010910A (en) | Pharmaceutical formulation of omeprazole | |
MXPA00005895A (en) | Oral pharmaceutical pulsed release dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |